Multi-Target Drugs for Kidney Diseases

Area of Science:

• Nephrology
• Pharmacology
• Computational Drug Design

Background:

• Kidney diseases, including acute kidney injury (AKI), chronic kidney disease (CKD), and glomerulonephritis (GN), present complex pathologies involving diverse cell types and signaling pathways.
• These intricate conditions often necessitate therapeutics capable of addressing multiple molecular targets simultaneously.

Purpose of the Study:

• To review the advancements and potential of multi-target drugs in treating complex kidney diseases.
• To highlight the role of in silico drug design in accelerating the development of such therapeutics.

Main Methods:

• Review of recent literature on multi-target drug development for kidney diseases.
• Analysis of computational (in silico) drug design strategies enabling multi-target approaches.
• Examination of drug mechanisms targeting inflammation, fibrosis, and metabolic dysfunction in renal pathologies.

Main Results:

• In silico drug design has significantly advanced the development of multi-target drugs over the past decade.
• Successful multi-target drugs have been developed for inflammatory, fibrotic, and metabolic diseases, with demonstrated potential in diabetic nephropathy and fibrotic kidney disease.
• These drugs effectively reduce renal TGF-β signaling, inflammation, mitochondrial dysfunction, and oxidative stress.

Conclusions:

• Multi-target drugs offer a promising therapeutic strategy for complex kidney diseases due to their ability to act on multiple cell types and signaling pathways.
• Further research and clinical testing are warranted for recently developed multi-target drugs to fully assess their efficacy in combating kidney diseases.